A proteomics approach to the identification of plasma biomarkers for latent tuberculosis infection

Diagnostic Microbiology and Infectious Disease

Volumn 79, Issue 4, 2014, Pages 432-437

  Zhang, Xia ^a   Liu, Fei ^a   Li, Qi ^a   Jia, Hongyan ^a   Pan, Liping ^a   Xing, Aiying ^a   Xu, Shaofa ^a   Zhang, Zongde ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Latent tuberculosis infection; MALDI TOF MS; Plasma; Proteomics

Indexed keywords

ALPHA TRYPSIN INHIBITOR H4; APOLIPOPROTEIN A1; APOLIPOPROTEIN A4; APOLIPOPROTEIN C3; BIOLOGICAL MARKER; CHAPERONIN 60; CHAPERONIN CONTAINING TCP1; COMPLEMENT COMPONENT C3; FIBRINOGEN A ALPHA CHAIN; FIBRINOGEN VARIANT; MYOSIN; MYOSIN 9; NADP DEPENDENT LEUKOTRIENE B4 12 HYDROXYDEHYDROGENASE; PEROXIREDOXIN 1; SUMO 1 PROTEIN; THYMOSIN BETA 4 LIKE PROTEIN 3; THYMOSIN BETA4; TRANSKETOLASE; TRYPSIN INHIBITOR; UNCLASSIFIED DRUG; PEPTIDE; PLASMA PROTEIN;

ACCURACY; ADULT; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; DIAGNOSTIC TEST ACCURACY STUDY; ELECTROSPRAY MASS SPECTROMETRY; FEMALE; HUMAN; LATENT TUBERCULOSIS; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; MALE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEOMICS; SCREENING; SENSITIVITY AND SPECIFICITY; TANDEM MASS SPECTROMETRY; TUBERCULIN TEST; VALIDATION PROCESS; WESTERN BLOTTING; BLOOD; CASE CONTROL STUDY; MASS SPECTROMETRY; MIDDLE AGED; PROCEDURES; REPRODUCIBILITY; RISK FACTOR; YOUNG ADULT;

ADULT; BIOLOGICAL MARKERS; BLOOD PROTEINS; CASE-CONTROL STUDIES; FEMALE; HUMANS; LATENT TUBERCULOSIS; MALE; MIDDLE AGED; PEPTIDES; PROTEOMICS; REPRODUCIBILITY OF RESULTS; RISK FACTORS; SENSITIVITY AND SPECIFICITY; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TUBERCULIN TEST; YOUNG ADULT;

EID: 84904131878     PISSN: 07328893     EISSN: 18790070     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2014.04.005     Document Type: Article

References (39)

1. Aichem A., Pelzer C., Lukasiak S., Kalveram B., Sheppard P.W., Rani N., et al. USE1 is a bispecific conjugating enzyme for ubiquitin and FAT10, which FAT10ylates itself in cis. Nat Commun 2010, 1:13.
2. Bandow J.E., Baker J.D., Berth M., Painter C., Sepulveda O.J., Clark K.A., et al. Improved image analysis workflow for 2-D gels enables large-scale 2-D gel-based proteomics studies-COPD biomarker discovery study. Proteomics 2008, 8:3030-3041.
3. Baumann S., Ceglarek U., Fiedler G.M., Lembcke J., Leichtle A., Thiery J. Standardized approach to proteome profiling of human serum based on magnetic bead separation and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Clin Chem 2005, 51:973-980.
4. Centers for Disease Control and Prevention (CDC) Targeted tuberculin testing and treatment of latent tuberculosis infection. American Thoracic Society. MMWR Recomm Rep 2000, 49:1-51.
5. Chen J.H., Chang Y.W., Yao C.W., Chiueh T.S., Huang S.C., Chien K.Y., et al. Plasma proteome of severe acute respiratory syndrome analyzed by two-dimensional gel electrophoresis and mass spectrometry. Proc Natl Acad Sci U S A 2004, 101:17039-17044.
6. Cheng A.J., Chen L.C., Chien K.Y., Chen Y.J., Chang J.T., Wang H.M., et al. Oral cancer plasma tumor marker identified with bead-based affinity-fractionated proteomic technology. Clin Chem 2005, 51:2236-2244.
7. Chien J.Y., Jerng J.S., Yu C.J., Yang P.C. Low serum level of high-density lipoprotein cholesterol is a poor prognostic factor for severe sepsis. Crit Care Med 2005, 33:1688-1693.
8. Dekker L.J., Burgers P.C., Charif H., van Rijswijk A.L., Titulaer M.K., Jenster G., et al. Differential expression of protease activity in serum samples of prostate carcinoma patients with metastases. Proteomics 2010, 10:2348-2358.
9. Deng C., Lin M., Hu C., Li Y., Gao Y., Cheng X., et al. Exploring serological classification tree model of active pulmonary tuberculosis by magnetic beads pretreatment and MALDI-TOF MS analysis. Scand J Immunol 2011, 74:397-405.
10. Dye C., Scheele S., Dolin P., Pathania V., Raviglione M.C. Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project. JAMA 1999, 282:677-686.
11. Endeman H., Meijvis S.C., Rijkers G.T., van Velzen-Blad H., van Moorsel C.H., Grutters J.C., et al. Systemic cytokine response in patients with community-acquired pneumonia. Eur Respir J 2011, 37:1431-1438.
12. Faulkner S., Elia G., Mullen M.P., O'Boyle P., Dunn M.J., Morris D. A comparison of the bovine uterine and plasma proteome using iTRAQ proteomics. Proteomics 2012, 12:2014-2023.
13. Fertin M., Burdese J., Beseme O., Amouyel P., Bauters C., Pinet F. Strategy for purification and mass spectrometry identification of SELDI peaks corresponding to low-abundance plasma and serum proteins. J Proteomics 2011, 74:420-430.
14. Fiedler G.M., Leichtle A.B., Kase J., Baumann S., Ceglarek U., Felix K., et al. Serum peptidome profiling revealed platelet factor 4 as a potential discriminating peptide associated with pancreatic cancer. Clin Cancer Res 2009, 15:3812-3819.
15. Huang Z., Shi Y., Cai B., Wang L., Wu Y., Ying B., et al. MALDI-TOF MS combined with magnetic beads for detecting serum protein biomarkers and establishment of boosting decision tree model for diagnosis of systemic lupus erythematosus. Rheumatology 2009, 48:626-631.
16. Ishigami N., Tokuda T., Ikegawa M., Komori M., Kasai T., Kondo T., et al. Cerebrospinal fluid proteomic patterns discriminate Parkinson's disease and multiple system atrophy. Mov Disord 2012, 27:851-857.
17. Jasmer R.M., Nahid P., Hopewell P.C. Clinical practice. Latent tuberculosis infection. N Engl J Med 2002, 347:1860-1866.
18. Komori M., Matsuyama Y., Nirasawa T., Thiele H., Becker M., Alexandrov T., et al. Proteomic pattern analysis discriminates among multiple sclerosis-related disorders. Ann Neurol 2012, 71:614-623.
19. Lassen N., Black W.J., Estey T., Vasiliou V. The role of corneal crystallins in the cellular defense mechanisms against oxidative stress. Semin Cell Dev Biol 2008, 19:100-112.
20. Lawn S.D., Zumla A.I. Tuberculosis. Lancet 2011, 378:57-72.
21. Liu Y.W., Yang M.H., Liu P.Y., Lee C.H., Liao P.C., Tyan Y.C. Proteomic analysis of pericardial effusion: characteristics of tuberculosis-related proteins. Proteomics Clin Appl 2008, 2:458-466.
22. Lu C., Wu J., Wang H., Wang S., Diao N., Wang F., et al. Novel biomarkers distinguishing active tuberculosis from latent infection identified by gene expression profile of peripheral blood mononuclear cells. PLoS One 2011, 6:e24290.
23. Martìnez Cordero E., Gonzàlez M.M., Aguilar L.D., Orozco E.H., Hernàndez Pando R. Alpha-1-acid glycoprotein, its local production and immunopathological participation in experimental pulmonary tuberculosis. Tuberculosis (Edinb) 2008, 88:203-211.
24. Menzies D. What does tuberculin reactivity after bacille Calmette-Guérin vaccination tell us?. Clin Infect Dis Suppl 2000, 3:S71-S74.
25. Mikkat S., Koy C., Ulbrich M., Ringel B., Glocker M.O. Mass spectrometric protein structure characterization reveals cause of migration differences of haptoglobin alpha chains in two-dimensional gel electrophoresis. Proteomics 2004, 4:3921-3932.
26. National Institute for Health and Clinical Excellence Tuberculosis: clinical diagnosis and management of tuberculosis, and measures for its prevention and control 2011, [Available at: http://guidance.nice.org.uk/CG117].
27. Pai M., Riley L.W., Colford J.M. Interferon-gamma assays in the immunodiagnosis of tuberculosis: a systematic review. Lancet Infect Dis 2004, 4:761-776.
28. Piñeiro M., Andrés M., Iturralde M., Carmona S., Hirvonen J., Pyörälä S., et al. ITIH4 (inter-alpha-trypsin inhibitor heavy chain 4) is a new acute-phase protein isolated from cattle during experimental infection. Infect Immun 2004, 72:3777-3782.
29. Sakamoto K., Geisel R.E., Kim M.J., Wyatt B.T., Sellers L.B., Smiley S.T., et al. Fibrinogen regulates the cytotoxicity of mycobacterial trehalose dimycolate but is not required for cell recruitment, cytokine response, or control of mycobacterial infection. Infect Immun 2010, 78:1004-1011.
30. Sandhu G., Battaglia F., Ely B.K., Athanasakis D., Montoya R., Valencia T., et al. Discriminating active from latent tuberculosis in patients presenting to community clinics. PLoS One 2012, 7:e38080.
31. Schwamborn K., Krieg R.C., Grosse J., Reulen N., Weiskirchen R., Knuechel R., et al. Serum proteomic profiling in patients with bladder cancer. Eur Urol 2009, 56:989-996.
32. Sester M., Sotgiu G., Lange C., Giehl C., Girardi E., Migliori G.B., et al. Interferon-γ release assays for the diagnosis of active tuberculosis: a systematic review and meta-analysis. Eur Respir J 2011, 37:100-111.
33. Shao L., Zhang W., Zhang S., Chen C.Y., Jiang W., Xu Y., et al. Potent immune responses of Ag-specific Vgamma2Vdelta2+ T cells and CD8+ T cells associated with latent stage of Mycobacterium tuberculosis coinfection in HIV-1-infected humans. AIDS 2008, 22:2241-2250.
34. Sterling T.R., Bethel J., Goldberg S., Weinfurter P., Yun L., Horsburgh C.R. The scope and impact of treatment of latent tuberculosis infection in the United States and Canada. Am J Respir Crit Care Med 2006, 173:927-931.
35. Sterling T.R., Villarino M.E., Borisov A.S., Shang N., Gordin F., Bliven-Sizemore E., et al. Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med 2011, 365:2155-2166.
36. Tufariello J.M., Chan J., Flynn J.L. Latent tuberculosis: mechanisms of host and bacillus that contribute to persistent infection. Lancet Infect Dis 2003, 3:578-590.
37. Wan J., Sun W., Li X., Ying W., Dai J., Kuai X., et al. Inflammation inhibitors were remarkably up-regulated in plasma of severe acute respiratory syndrome patients at progressive phase. Proteomics 2006, 6:2886-2894.
38. Wong M.Y., Yu K.O., Poon T.C., Ang I.L., Law M.K., Chan K.Y., et al. A magnetic bead-based serum proteomic fingerprinting method for parallel analytical analysis and micropreparative purification. Electrophoresis 2010, 31:1721-1730.
39. World Health Organization (WHO) Standard tuberculin test. WHO/TB/Technical Guide/85.145 1963, [Geneva, Switzerland].